HC Wainwright reissued their buy rating on shares of Fennec Pharmaceuticals (NASDAQ:FENC – Get Rating) in a report published on Friday morning, Benzinga reports. HC Wainwright currently has a $18.00 target price on the stock. HC Wainwright also issued estimates for Fennec Pharmaceuticals’ Q1 2024 earnings at $0.03 EPS, Q2 2024 earnings at $0.10 EPS, […]
Fennec Pharmaceuticals (NASDAQ:FENC – Get Rating)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued on Friday, Benzinga reports. They presently have a $18.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 110.53% from the stock’s current price. Fennec Pharmaceuticals Trading Up […]
Fennec Pharmaceuticals (NASDAQ:FENC – Get Rating) released its quarterly earnings results on Thursday. The company reported ($0.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.02), Yahoo Finance reports. Fennec Pharmaceuticals Price Performance Shares of FENC opened at $8.55 on Friday. The company has a market capitalization of $225.81 […]
Fennec Pharmaceuticals (NASDAQ:FENC – Get Rating) and Adaptive Biotechnologies (NASDAQ:ADPT – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, institutional ownership, profitability and analyst recommendations. Volatility & Risk Fennec Pharmaceuticals has a beta of […]